Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : PJ July 2015 online

Sort by: Newest first Oldest first A-Z Z-A

  • QT interval prolongation with Zytiga Subscription

    29 JUL 2015 8:54

    Prolongation of the QT interval has been added as an adverse event with unknown frequency to the summary of product characteristics (SPC) for Zytiga (abiraterone; Janssen-Cilag). The updated SPC now advises caution when administering Zytiga with medicinal products known to prolong the QT interval or those able to induce torsade de pointes.

  • The US Food and Drug Administration has approved sonidegib (Novartis’s Odomzo) as a treatment for patients with locally advanced basal cell carcinoma (micrograph pictured) that has recurred following surgery or radiation therapy

    Skin cancer drug sonidegib approved in United States Subscription

    28 JUL 2015 16:28

    The US Food and Drug Administration has approved sonidegib as a treatment for patients with locally advanced basal cell carcinoma.

  • AWMSG medicines approvals Subscription

    27 JUL 2015 9:53

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Darunavir, in combination with other antiretrovirals, for treating human immunodeficiency virus-1 infection in children aged at least three years and weighing 15kg and over; peginterferon beta-1a for treating adults with relapsing-remitting multiple sclerosis; regorafenib for treating adults with unresectable or metastatic gastrointestinal stromal tumours who progressed ...

  • Ash Soni has been re-elected as president of the Royal Pharmaceutical Society (RPS) at a meeting of the RPS assembly on 21 July 2015

    Soni re-elected Royal Pharmaceutical Society president Subscription

    22 JUL 2015 15:28

    Ash Soni has been re-elected as president of the Royal Pharmaceutical Society (RPS) at a meeting of the RPS assembly on 21 July 2015.

  • Researchers have elucidated the reasons why an HIV-1 vaccine, RV144, led to a mixed response in terms of HIV-1 infection risk. In the image, micrograph of HIV-1 budding (green) from cultured lymphocyte

    Genetics may play a role in efficacy of HIV vaccine Subscription

    21 JUL 2015 10:22

    Variation in individuals immune response genes could explain why the vaccine worked in some but not others.

  • The role of advanced practice pharmacists in primary care is being developed in Wales as part of the government’s workforce plans for the next three years. The project was launched by Mark Drakeford (pictured), Welsh health minister

    Welsh government pledges support for advanced practice pharmacists Subscription

    20 JUL 2015 16:53

    The role of advanced practice pharmacists in primary care is being developed in Wales as part of the government’s workforce plans for the next three years.

  • The pharmaceutical care of people with learning disabilities (pictured) is failing to deliver basic standards and needs urgent reform, including a greater role for pharmacists, the Royal Pharmaceutical Society (RPS) says.

    'Urgent reform' to pharmaceutical care for people with learning disabilities needed, says RPS Subscription

    20 JUL 2015 15:01 By Stephen Robinson

    Current system of care failing to deliver basic standards for patients, Society warns.

  • Worldwide an estimated 246 million people - or slightly more than 5% of those aged 15 to 64 years - used an illicit drug in 2013, up by three million over the previous year, according to the World Drug Report, 2015

    Illicit drug users are on the rise, finds UN report Subscription

    10 JUL 2015 15:17

    Worldwide an estimated 246 million people used an illicit drug in 2013, a rise of three million over the previous year, says a report by the UN Office on Drugs and Crime.

  • Drug alert for Xenidate XL Subscription

    10 JUL 2015 12:43

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for a small number of packs from a specific batch of Xenidate XL (methylphenidate hydrochloride; Mylan UK) prolonged-release tablets 36mg. Further information ...

  • More information required for ciclosporin Subscription

    10 JUL 2015 12:20

    The National Institute for Health and Care Excellence (NICE) has published draft guidance asking Santen Pharmaceutical for more information about ciclosporin (Ikervis) for treating severe keratitis in adults with dry eye disease that has not improved despite treatment with artificial tears. NICE has requested additional information about the cost and clinical effectiveness of the drug.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.